Elevated levels of circulating IL-6 and sIL-6R, on the other hand, frequently accompany pathophysiologic conditions and constitute potential drug targets in the treatment of diseases like rheumatoid arthritis, asthma, and multiple sclerosis (3, 12, 17, –, 19). This evidence concerns the gene IL6 and rheumatoid arthritis.